Cognito Therapeutics Presents AAIC 2026 Data Linking Spectris Neurostimulation to Lipid Transport Biomarkers in Alzheimer's

Summary

Cognito Therapeutics presented exploratory cerebrospinal fluid proteomics data at the Alzheimer's Association International Conference 2026, from its Phase 2 FLICKER study of the investigational Spectris sensory-stimulation platform in 10 amyloid-positive mild cognitive impairment patients. An unbiased mass spectrometry screen showed daily Spectris treatment was associated with higher CSF concentrations of a group of HDL-like lipid transport proteins, alongside signs of a myelination-related biological pathway, echoing earlier MRI work suggesting the therapy may help preserve white matter. CEO Christian Howell described the findings as reinforcing the company's hypothesis about Spectris' biological mechanism, while noting the analyses remain exploratory.